Featured Research

from universities, journals, and other organizations

Increased Dosage of Vancomycin May Lead to Hearing Loss in Older Patients

Date:
March 4, 2009
Source:
American Society for Microbiology
Summary:
A new study suggests that increasingly aggressive doses of vancomycin being prescribed to keep pace with the rising number of methicillin-resistant Staphylococcus aureus (MRSA) infections may cause high-frequency hearing loss in older patients.

A new study suggests that increasingly aggressive doses of vancomycin being prescribed to keep pace with the rising number of methicillin-resistant Staphylococcus aureus (MRSA) infections may cause high-frequency hearing loss in older patients.

The researchers from New York Medical College, Valhalla, New York, the University of the Pacific School of Pharmacy, Stockton, and Sharp Memorial Hospital, San Diego, CA report their findings in the February 2009 issue of the journal Antimicrobial Agents and Chemotherapy.

Although vancomycin has been available to medical professionals for 50 years, the emergence and rapid rise of MRSA in both community and healthcare settings has greatly increased its use. Additionally, recent increases in vancomycin minimum inhibiting concentrations (MICs) among MRSA isolates has resulted in many clinicians upping the dosage prescribed to patients.

In the study 89 patients taking vancomycin ranging in age from 16 to 86 were evaluated for high-frequency hearing loss detected by audiometry. They were administered a baseline audiogram (3 days after initiation of therapy) and then a follow-up test after an average of 27 days of therapy. Results showed a 12% rate of high-frequency hearing loss with a trend toward a higher rate with advanced age. Further analysis demonstrated a 0% rate of high-frequency hearing loss in patients under the age of 53 and a rate of 19% for patients over the age of 53.

"We conclude that a significant rate of high-frequency hearing loss in older patients receiving vancomycin monotherapy was detected by audiometry," say the researchers. "These findings should provide an additional caution against the use of indiscriminately higher doses of vancomycin to chase increasing vancomycin MICs for MRSA strains causing serious infections, such as pneumonia or bacteremia, in older patients."


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Forouzesh, P.A. Moise, G. Sakoulas. Vancomycin ototoxicity: a reevalutaion in an era of increasing doses. Antimicrobial Agents and Chemotherapy, 53. 2: 483-486

Cite This Page:

American Society for Microbiology. "Increased Dosage of Vancomycin May Lead to Hearing Loss in Older Patients." ScienceDaily. ScienceDaily, 4 March 2009. <www.sciencedaily.com/releases/2009/03/090304091339.htm>.
American Society for Microbiology. (2009, March 4). Increased Dosage of Vancomycin May Lead to Hearing Loss in Older Patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/03/090304091339.htm
American Society for Microbiology. "Increased Dosage of Vancomycin May Lead to Hearing Loss in Older Patients." ScienceDaily. www.sciencedaily.com/releases/2009/03/090304091339.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins